Herpesviruses attach to host cells by interacting with cell surface heparan sulfate (HS) 26 proteoglycans prior to specific coreceptor engagement which culminates in virus-host 27 membrane fusion and virus entry. Interfering with HS-herpesvirus interactions results in 28 significant reduction in virus infectivity indicating that HS play important roles in initiating 29 virus entry. In this study, we provide convincing evidence that specific sulfations as well 30 as the degree of polymerization (dp) of HS govern human cytomegalovirus (CMV) 31 infection and binding by following line of evidences. First, purified CMV extracellular 32 virions preferentially bound to the sulfated longer chain of HS on a glycoarray compared 33 to unsulfated glycosaminoglycans and shorter chain unsulfated HS. Second, the fraction 34 of glycosaminoglycans (GAG) displaying higher dp and sulfation had a major impact on 35 CMV infectivity and titers. Finally, cell lines knocked out for specific sulfotransferases 36
Abstract 24
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Glucosaminyl 3-O-sulfotransferase (3-O-ST-1 and -4 and double -1/4) produced 37 significantly reduced CMV titers compared to wild-type cells. Similarly, a peptide 38 generated against sulfated-HS significantly reduced virus titers compared to the control 39 peptide. Taken together, the above results highlight the significance of the chain length 40 and sulfation patterns of HS in CMV binding and infectivity.
Importance 42 43
The cell surface heparan sulfates (HS) are exploited by multiple viruses as they provide 44 docking sites during cell entry and therefore are a promising target for the development 45 of novel antivirals. In addition, the molecular diversity in HS chains generates unique 46 binding sites for specific ligands and hence offers preferential binding for one virus over 47
Introduction 53 54
The heparan sulfate (HS) proteoglycans are present on most cell types and function as 55 primary cellular receptor for medically important viruses, including human 56 immunodeficiency virus (HIV), hepatitis-C virus (HCV), human papillomavirus (HPV), 57
and Dengue virus (DENV) human cytomegalovirus (HCMV), at least twenty three different viral glycoproteins have 76 been found to be associated with purified virion preparations 14 . For most herpesviruses, 77 the conserved glycoprotein B (gB) is required for virus entry and binds to cell surface 78 molecules, including HS, which is present not only as a constituent of cell surface 79 proteoglycans but also as a component of the extracellular matrix and basement 80 membranes in organized tissues 5, 15 . HCMV gB binds to HS resulting in virus 81 .
86
The synthesis of HS is a complex process involving multiple specialized enzymes 87 and is initiated from a tetrasaccharide (GlcA-Gal-Gal-Xyl) that is attached to the core 88 protein (Fig 1) . HS polymerase is responsible for building the polysaccharide backbone 89 with a repeating unit of -GlcA-GlcNAc- (Fig 2) . The backbone is then modified by N-90
IdoA units and the size of the polysaccharides 21 . The location of the sulfo groups and 98
IdoA in turn play a crucial role in determining the binding and functions of HS. 99
The enzymatic modification of HS chain is known to generate unique binding 100 sites for viral ligands. For example, 3-O-sulfation modification in HS chain generates 101 fusion receptor for HSV glycoprotein D (gD) promoting viral entry and spread 23 . The 3-102 O-S HS is a product of enzymatic modification at C3 position of glucosamine residue, 103 which is relatively rare in comparison to other HS modifications (Fig 2) . Expression of 104
Hs3st can make normally resistant Chinese hamster ovary (CHO-K1) cells susceptible 105
to HSV-1 infection 24 . Studies in clinically relevant primary human corneal fibroblasts 106 have also shown 3-O-S HS as a primary receptor for HSV entry 25 . Interestingly, both 107
HSV-1 and HSV-2 use HS as an attachment receptor but HSV-1 binds to distinct 108 modification sites on HS that HSV-2 is unable to, which could explain some of the 109 differences in cell tropism exhibited by these two viruses 26 . For example, while N-110 sulfation and carboxyl groups are required for both HSV-1 and HSV-2 binding, only 111 HSV-1 is able to bind the specific modification sites generated by 2-O, 6-O, and 3-O-112 HS significantly enhanced cell fusion. A similar trend of enhanced fusion was observed 121 with cells expressing HCMV glycoproteins (gB, gO, and gH-gL) 2, 33, 34 . 131
The inhibitory activity of HS mimics, including these compounds, is believed to be due 132 to their association with GAG binding sites of the putative receptor-binding domain on 133 the viral protein 2, 35 . Thus, HS mimics can inhibit virus adsorption and entry. 134
In the current study, we investigated the impact of specific sulfations as well as 135 degree of polymerization (dp) in HS chain on both human and mouse CMV infection 136 and binding. Purified CMV extracellular virions preferentially bound strongly to the 137 longer chain sulfated HS but not to the shorter chain unsulfated HS on a glycoarray. 138
Glycosaminoglycans of different dp were derivatized from enoxaparin (a low molecular 139 weight heparin) and tested for their ability to inhibit CMV infection in cell culture. The 140 results show that longer glycan chains are more efficient at reducing CMV titers in cells 141 compared to shorter chain glycans. Finally, the cell lines defective in 3-O-ST -1 and -4 142 expression had reduced CMV replication. Moreover, a peptide generated against thesulfated-HS significantly reduced HCMV titers compared to control peptide. Overall, 144 these results indicate that CMV binding to cell surface glycans is dependent on branch 145 length and sulfation pattern of HS. 146
147

Materials and Methods 148
Preparation of Glycosaminoglycans (GAGs) oligosaccharides. 150
Glycosaminoglycans of different dp were fractionated from enoxaparin (a low molecular 151 weight heparin) by Bio-Gel P-10 chromatography as previously described 36 . Briefly, 30 152 mg/2 mL Enoxaparin Sodium derived from porcine intestinal mucosa (Sanofi-Aventis 153 U.S., Bridgewater, NJ) was applied to a Bio-Gel P-10 column (2.5×120 cm, Bio-Rad, 154
Hercules CA) and eluted with 0.2 M NH 4 HCO 3 at a flow rate of 14 mL/h. Elution of 155 oligosaccharides was monitored by absorbance at 232 nm. NH 4 HCO 3 was removed by 156 heating in oven at 50°C for 24 h.
antibody (Goat anti mouse IgG AlexaFlour555) was done at 1µg/ml. Maximum strength 236 fluorescent signal was obtained for 10 8 pfu/ml concentration of the virus, therefore, only 237 this concentration is represented in the final data obtained for plotting the graphs. 238
239
Effect of anti-HS and anti-3OS HS peptide on CMV entry. HFF cells were pre-treated 240 with the phage display derived peptides (1 mg/ml) generated against wild-type HS 241 
252
HCMV extracellular virions were purified as described above and incubated with custom 253 glycoarrays containing increasing molecular weight species of hyaluronic acid, heparin, 254 chondroitin sulfate, and dermatan sulfate ( Table 1) . As indicated in Fig. 3 HCMV binding  255 to non-sulfated hyaluronic acid (HA10 to HA20 and HA93 polymer) was negligent but 256 significant binding to all heparin species was detected with a trend of increased binding 257 to heparins as their dp increased. HCMV also showed binding to large size chondroitinsulfate D , and dermatan sulfate oligosaccharides (DS16-20) but not to 259
Chondroitin Sulphate AC (CS-AC). It is important to note that while the CS-A is sulfated 260 at C4 of the GalNAc, and the CS-C is sulfated at the C6 of the GalNAc only, the CS-D is 261 sulfated at C2 of the glucuronic acid as well as the C6 of the GalNAc sugar and hence 262 has double the amount of sulfation compared to CS-A and CS-C. Dermatan sulfate, 263 formerly referred to as CS-B, is formed from the polymer backbone of chondroitin 264 sulfate by the action of chondroitin-glucuronate C5 epimerase, which epimerizes 265 individual d-glucuronic acid residues to l-iduronic acid. The binding affinity to DS was 266 also size-dependent increasing from DS16 to DS20. Heparin (dp30) was the best binder 267 in this assay. 268
On a second HS specific array (Table 2) , HCMV showed decent specific binding 269 to sulfated HS with stronger binding to the HS with longer disaccharide chains (HS007 270 to HS024) (Fig 4) . HCMV showed minimal binding to unsulfated glycans (HS001-271 HS006). The maximum binding was observed for HS014, HS015 and HS016, which are 272 all 6-O-S 9-mers with moderate amount of sulfation (1.3-1.8 sulfate group per 273 disaccharide). Also, significant amount of binding was observed for 2-O-S (HS17-274 HS19), 6-O-S/2-O-S (HS20-22) and 2-O-S/6-O-S/3-O-S (HS23-24) HS that had high 275 amount of sulfation (1.3-2.7 sulfate group per disaccharide) and 6-8 disaccharide per 276 chain. Overall the data from these experiments indicate that the dp of HS as well as 277 sulfation is important for HCMV binding. 278
279
The degree of polymerization of GAG chains impacts CMV infectivity. 280
Glycosaminoglycans of different dp were fractionated from enoxaparin (a low molecular 282 weight heparin). All of these GAGs are based on a HS backbone and differ in either dp 283 or degree/place of sulfation or both (Fig 5, S1-S3 ). These GAGs, along with heparin and 284 Arixtra (fondaparinux sodium), were first screened in a GFP-based virus focus reduction 285 assay using GFP tagged HCMV (Towne strain). The viral GFP expression was most 286 efficiently reduced by heparin salt (PIHSS; Heparin sodium salt from porcine intestinal 287 mucosa) whereas arixtra, 6-O-desulfated arixtra and Enoxaparin had little to no impact 288 on GFP expression (Fig 5) . In general, enoxaparin derived GAGs with higher dp were 289 more efficient in reducing viral GFP compared to low dp derivatives. This screening 290 assay when performed at a range of GAG concentrations (10nM to 100µM) determined 291 10µM as the most effective concentration at reducing viral titers with no additional 292 reduction seen at >10µM concentrations (data not shown). To follow up on this primary 293 GFP based screening, we performed viral titer assay using HCMV (Towne strain) that 294 measures total virus yields at 5 days post infection. Most reduction in viral titers was 295 observed for heparin (PIHSS) followed by enoxaparin derivative with >20 dp (Fig 6A) . 296
Plotting of viral titer reduction as a function of dp revealed a general trend where higher 297 dp derivatives lead to higher reduction in viral titers ( Fig 6B) . Thus, this experiment 298 indicated that longer HS chains are more efficient at reducing HCMV titers in cells. To 299 investigate whether this inhibitory effect was due to an increase in avidity of longer 300 chain GAGs towards virus particles, the experiments were repeated at 0.05 g/L 301 concentrations of GAGs (Fig 7A) . Similar trend of inhibitory results leaning towards 302 efficacy of higher dp against HCMV infection were obtained at 0.05 g/L indicating that 303 this effect is dictated by the molecular composition of GAG and is not a mere effect ofincreased avidity. A line graph for each concentration of GAGs was generated that 305 demonstrates the relationship of viral titer and degree of polymerization ( Fig 7B) . To 306 investigate whether some of these effects on virus titers could be attributed to cell 307 death, we performed cell viability assays in both uninfected and infected settings. Cell 308 viability was not affected at the treated concentrations of any of our test GAGs (Fig 8A) . 309
Moreover, heparin (PIHSS) and enoxaparin derivatives (dp 12 or greater) efficiently 310 protected cells from virus induced lytic death (Fig 8B ) . These results corroborate the 311 results of our glycoarray experiments that showed that GAG with higher dp have higher 312
CMV binding compared to GAG with lower dp (Fig 4) . binding. In the preliminary experiment, GFP tagged HCMV was used and the number of 355 GFP+ foci was quantified. The data from this experiment indicated that viral GFP was 356 more effectively reduced when cells were pretreated with GAGs having a higher dp (Fig  357   5 ). For a deeper understanding of this reduction, we performed a similar experiment 358 where HCMV towne strain was used and viral load was quantified at 5 days post 359 infection. Significant reduction in virus titers was observed in samples treated with 360
higher dp of GAG but not with lower dp corroborating the results from glycoarray 361 experiments that chain length of GAG is an important factor in determining HCMV 362 binding. Also, this effect was not due to combined affinities of multiple binding sites on 363
GAGs as evidenced by similar trend of inhibition obtained when treating cells with 364 equivalent µM or µg/ml concentrations of GAGs. Treatment of cells with these GAGs did 365 not affect their viability for the duration of treatment (Fig 8A) confirming that the 366 observed reduction in virus titer was not due to the cell death. Moreover, cells 367 pretreated with GAGs associated with longer dp resisted infection induced cell death at 368 late time post infection (Fig 8B) . We also tested the impact of specific HS sulfation 369 mutants on MCMV infection. As 3-O sulfation has been reported to be critical for 370 herpesvirus entry 25, 28 , we tested MCMV growth in Hs3st1, Hs3st4 and dual Hs3st1/4 371 knockout cells. For both high and low MOI, virus titer was significantly reduced inHs3st1, Hs3st4 and dual Hs3st1/4 knockout cells (Fig 9) . Additional data from anti-3-O-373 S HS peptide confirmed the significance of sulfation in HCMV infectivity. 374
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